GRx+Biosims 2020
Overview
GRx+Biosims 2020 is the premier scientific and regulatory event for the U.S. generics and biosimilars industries, featuring timely programming relevant to technical, regulatory and policy professionals.
Top officials and subject-matter experts share their knowledge and best practices to enhance attendees’ understanding of how to succeed in generic and biosimilar development; the regulatory process and approvals: and the evolving policy landscape.
The mission of providing America’s patients with access to the generic and biosimilar medicines they need remains our top priority. As this country faces the challenges of COVID-19, the importance of our mission comes into clearer focus – and the need to share knowledge and best practices has even greater urgency.
Due to public health and safety concerns related to the coronavirus (COVID-19) pandemic, we decided to web-stream the conference. The format may be new but will still allow you to participate in Q&A with speakers, engage with your peers and meet with exhibitors.
DateNovember 9-11, 2020 | Virtual Conference
Standard Virtual Registration- AAM Member Attendee Fee
Biosimilars Council Attendee Fee
$1,550.00
Nonmember Attendee Fee
$1,850.00
Government Attendee Fee
$500.00
Latest News
Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of transfusion-dependent beta thalassemia (TDT).
LEARN MOREPfizer Acquires Amplyx Pharmaceuticals
Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems.
LEARN MOREJanux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials
Janux Therapeutics today announced the closing of a $125 million Series B financing led by RA Capital Management and joined by new investors BVF Partners L.P., EcoR1 Capital, Hartford HealthCare Endowment, Janus Henderson Investors, Logos Capital, Samsara BioCapital and Surveyor Capital (a Citadel company).
LEARN MORE